-
Enhancing Proteotoxic Cell Death in Prostate Cancer via Renc
2026-04-17
This study demonstrates that combining the cyclophilin inhibitor rencofilstat with the proteasome inhibitor ixazomib selectively amplifies proteotoxic apoptosis in advanced prostate cancer cells, while sparing non-cancerous cells. The findings clarify the roles of ER stress response pathways and suggest new strategies for overcoming resistance in castration-resistant and neuroendocrine prostate cancer.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin: Mechanistic In
2026-04-16
Wu et al. (2025) provide compelling evidence that centromere protein I (CENPI) acts as an oncogene in breast cancer, promoting tumorigenesis and disease progression through modulation of Wnt/β-catenin signaling. Their integrative approach combining clinical data, cell-based assays, and molecular pathway analysis highlights CENPI as both a potential biomarker and therapeutic target.
-
Thiamet G: Applied Workflows for O-GlcNAcase Inhibition in R
2026-04-15
Thiamet G, a potent and selective O-GlcNAcase inhibitor from APExBIO, enables precise modulation of O-GlcNAcylation for advanced disease modeling. Explore optimized experimental protocols, troubleshooting strategies, and real-world insights to unlock its full potential across neurodegeneration, leukemia sensitization, and bone metabolism research.
-
Sumatriptan Succinate: Advancing Translational Migraine Rese
2026-04-14
Explore the latest scientific advances using Sumatriptan Succinate as a 5-HT1 receptor agonist in translational migraine research. Uncover unique pediatric findings, mechanistic insights, and expert protocol guidance for innovative assay development.
-
Nonivamide (Capsaicin Analog): Protocols for Cancer and Infl
2026-04-13
Nonivamide, a selective TRPV1 agonist, offers unique advantages for cancer cell growth inhibition and inflammation modulation. This article translates cutting-edge evidence and practical workflows into reliable, data-driven protocols for biomedical researchers leveraging Nonivamide in oncology and neuroimmune studies.
-
Bradykinin: Endothelium-Dependent Vasodilator in Research Wo
2026-04-13
Bradykinin, a gold-standard endothelium-dependent vasodilator peptide from APExBIO, enables precise vascular permeability and inflammation studies. This guide unpacks advanced experimental workflows, troubleshooting insights, and how recent findings in cellular signaling can directly inform assay design and data reliability.
-
Prochlorperazine in Translational Oncology: Mechanistic Insi
2026-04-12
Explore the multifaceted role of Prochlorperazine as a dopamine D2 receptor antagonist in cancer research and clinical therapy. This article uniquely bridges molecular pharmacology with safety evidence, offering new perspectives for oncology workflows.
-
Vorinostat in Cancer Biology: Applied Workflows & Optimizati
2026-04-12
Vorinostat (suberoylanilide hydroxamic acid) delivers precise, reproducible epigenetic modulation in cancer models, enabling robust apoptosis assays and gene expression studies. This guide translates bench-proven protocols, advanced applications, and troubleshooting strategies to help researchers maximize data quality and experimental impact with Vorinostat from APExBIO.
-
Clarithromycin as a CYP3A Inhibitor: Optimizing Drug Interac
2026-04-11
Clarithromycin from APExBIO empowers researchers to precisely inhibit CYP3A activity, enhancing the reliability of pharmacokinetic and drug-drug interaction workflows. This article delivers actionable protocols, advanced troubleshooting, and translational insights—bridging cardiovascular and metabolic research for reproducible, high-impact results.
-
AG-490 (Tyrphostin B42): Precision Inhibition of JAK2/STAT6
2026-04-11
AG-490 stands out as a potent JAK2/EGFR inhibitor for dissecting immune and cancer signaling in translational research, with robust evidence for modulating macrophage polarization. This guide delivers applied workflows, protocol enhancements, and troubleshooting insights, grounded in the latest mechanistic findings from hepatocellular carcinoma studies.
-
Practical Application of Apigenin in Mesothelioma Cell Studi
2026-04-10
Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) enables researchers to investigate malignant mesothelioma cell growth inhibition and apoptosis induction via HDAC inhibition, with specific solubility and dosing considerations. This compound is not intended for diagnostic or clinical use; its utility is confined to in vitro and preclinical workflow settings where mechanistic and phenotypic responses can be measured.
-
Vorinostat (SAHA): Epigenetic Modulation and Novel Apopto...
2026-04-10
Discover how Vorinostat (SAHA), a leading HDAC inhibitor for cancer research, uniquely orchestrates epigenetic modulation and intrinsic apoptotic pathway activation. Explore advanced insights into its mechanism, including new evidence on RNA Pol II–mediated apoptosis and applications across experimental oncology.
-
Thiamet G: Potent Selective O-GlcNAcase Inhibitor for O-G...
2026-04-09
Thiamet G is a potent, selective O-GlcNAcase inhibitor that enables precise modulation of cellular O-GlcNAcylation. Its high affinity, stability, and blood-brain barrier penetration make it the gold standard for inhibition of tau phosphorylation and metabolic pathway studies.
-
Advancing Translational Oncology with Entinostat (MS-275,...
2026-04-08
This thought-leadership article explores the mechanistic foundations and translational potential of Entinostat (MS-275, SNDX-275), a selective oral HDAC1/3 inhibitor. Integrating recent findings on histone deacetylase (HDAC) signaling in regeneration and cancer, we provide strategic guidance for researchers navigating the complexities of epigenetic modulation in oncology. We contextualize Entinostat’s unique value in experimental and clinical workflows, highlighting its differentiation, evidence base, and forward-looking applications.
-
Belinostat (PXD101): Practical Guidance for Reliable HDAC...
2026-04-08
This scenario-driven article provides bench-level guidance for leveraging Belinostat (PXD101) (SKU A4096) as a pan-HDAC inhibitor in cell viability, proliferation, and cytotoxicity assays. With emphasis on reproducibility, IC50 benchmarking, and workflow compatibility, the article equips biomedical researchers with actionable strategies for experimental design and data interpretation. Explore how Belinostat (PXD101) from APExBIO addresses real-world laboratory challenges to advance epigenetic cancer research.